IDE Application (Investigational Device Exemption Application)

An IDE application (Investigational Device Exemption application) is the package a sponsor submits to FDA’s Center for Devices and Radiological Health (CDRH) under 21 CFR 812.20, requesting authorization to ship and use an investigational medical device in a clinical study before that device has been cleared (510(k)) or approved (PMA) for commercial distribution. Approval of the application — or, for most non-banned devices, the simple passage of 30 days after FDA receives it without an FDA hold — is what makes the study lawful to begin. Only significant risk (SR) device studies require a full IDE application; nonsignificant risk (NSR) studies are handled through abbreviated, IRB-reviewed requirements and generally are not submitted to FDA as a formal application at all. See Investigational Device for the full SR/NSR determination criteria under 21 CFR 812.3(m); this entry focuses on the application and review mechanics themselves.

What the application must contain (21 CFR 812.20(b))

A complete IDE application, filed in order per 812.20(b), includes:

• Sponsor information — name and address of the sponsor.
• Report of prior investigations — a complete report of prior investigations of the device (nonclinical/bench, animal, and any earlier clinical data), plus either the complete investigational plan or an accurate summary of it, depending on whether an IRB has already reviewed the plan.
• Investigational plan — purpose, protocol, risk analysis, device description, monitoring procedures, and labeling for the study.
• Manufacturing information — a description of methods, facilities, and controls for manufacture, processing, packing, storage, and installation, sufficient for someone familiar with good manufacturing practice to assess device quality.
• Investigator agreements and list — an example of the agreement each investigator will sign, and a complete list of investigators who have already signed one, with certification that no additional investigator will be added without a signed agreement.
• IRB information — names, addresses, and chairpersons of every reviewing IRB, plus certification of IRB action on the study.
• Additional institutions — any study site not already identified through the IRB information.
• Sales justification, if the device will be sold during the investigation — the amount charged and an explanation of why the sale does not constitute commercialization.
• Environmental documentation — a claim for categorical exclusion, or an environmental assessment.
• Labeling — copies of all device labeling used in the investigation.
• Informed consent materials — copies of all forms and information provided to subjects to obtain consent.
• Any other information FDA requests to review the application.

FDA review: the 30-day clock (21 CFR 812.30)

FDA notifies the sponsor in writing of the date it receives the application, then may approve the investigation as proposed, approve it with conditions/modifications, or disapprove it. For most device investigations (banned devices are handled differently), the study may begin once either of two things happens: FDA affirmatively approves the IDE by order, or 30 days pass after FDA’s receipt of the application without FDA notifying the sponsor that the study may not begin. That default-permission structure — silence after 30 days functions as clearance to proceed — mirrors the same default-permission design FDA uses for drug/biologic IND applications under 21 CFR Part 312, though the device and drug regulations remain separate frameworks with separate application content. See IND vs. IDE for a fuller side-by-side of the two pathways.

After approval: supplements and reports

An approved IDE is not static. Sponsors must submit a supplement before making most changes to the investigational plan or protocol (21 CFR 812.35), and must meet ongoing reporting obligations to FDA and participating IRBs, including annual progress reports and unanticipated adverse device effect reports, for as long as the IDE remains in effect. Significant changes affecting subject safety generally require FDA and IRB approval before being implemented, rather than being reported after the fact.

Worked example

Illustrative composite, not a real study. A device sponsor developing an implantable neurostimulator intended to support a future PMA submission determines, with IRB concurrence, that the device is significant risk under 812.3(m) because it is an implant presenting potential for serious risk. The sponsor prepares a full 812.20(b) application — including bench and animal data, the clinical protocol, manufacturing information, and investigator agreements — and submits it to CDRH. Hearing nothing from FDA within 30 days, and having also obtained IRB approval and finalized informed consent documents, the sponsor begins enrollment on day 31.

Counter-example

A sponsor studying a software algorithm running on already-cleared, unmodified imaging hardware, evaluated non-invasively with no direct patient-management decisions based on study data alone, has its device determined nonsignificant risk by the reviewing IRB. The sponsor still follows abbreviated IDE requirements — appropriate labeling, IRB approval, monitoring, recordkeeping, and informed consent — but does not prepare or submit a 812.20(b) application to FDA at all, unless FDA later notifies the sponsor otherwise.

Related terms

• Investigational Device — the regulatory status (and the SR/NSR determination) that decides whether a full IDE application is required in the first place.
• IND vs. IDE — how the drug/biologic pathway (Part 312) and the device pathway (Part 812) compare.
• Investigational New Drug (IND) — the drug-side analog application, reviewed under a similar default-permission clock but a distinct regulation.
• Investigational Medicinal Product (IMP) — the equivalent EU/international term for an investigational drug, for comparison with how devices are classified.
• Humanitarian Use Device (HUD) — a related device pathway (Humanitarian Device Exemption) for rare-condition devices, distinct from a standard IDE study.
• Institutional Review Board (IRB) — reviews and approves both SR and NSR device investigations alongside FDA.